UPDATE: Morgan Stanley Reiterates On St. Jude Medical On Mixed Factors
In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on St. Jude Medical (NYSE: STJ), but removed the $75.00 price target.
In the report, Morgan Stanley noted, “We remain comfortable that St. Jude's top line is poised for acceleration given underlying business strength, CRT-D momentum and CardioMEMs. However, Nanostim's early European failures and MDT's more positive comparative experience did raise concerns at HRS.”
St. Jude Medical closed on Thursday at $63.22.
Latest Ratings for STJ
|Dec 2014||Credit Suisse||Maintains||Outperform|
|Nov 2014||Cowen & Company||Upgrades||Market Perform||Outperform|
|Oct 2014||Stifel Nicolaus||Maintains||Buy|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.